Apyx Medical gets FDA nod for new Renuvion cosmetic product

• Apyx Medical Corporation (NASDAQ:APYX) announced Wednesday that the FDA granted 510(k) clearance for Renuvion Micro Handpiece, a new product in its family of skin-tightening devices.
• Renuvion Micro Handpiece is indicated "for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue," the company said.
• Compared to the Apyx's (APYX) Renuvion APR Handpiece, Renuvion Micro Handpiece features a smaller instrument shaft. The device works on the company's Apyx One Console, a multi-functional generator system launched in early 2023.
• "It complements our existing product portfolio, providing our customers with a new option to facilitate soft tissue contraction in those cases that may benefit from the use of a handpiece with a smaller profile," CEO Charlie Goodwin remarked.
• Apyx (APYX) expects a limited commercial launch of Renuvion Micro Handpiece in Q3 2023.

More on Apyx

• Apyx gets FDA nod for Renuvion APR Handpiece use after liposuction
• Apyx Medical wins FDA nod for Renuvion APR Handpiece in new indication